{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:39Z","timestamp":1791563379702,"version":"4.3.4"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Low-density lipoprotein cholesterol (LDL-C) is the main target for therapeutics aimed at reducing the risk of atherosclerotic cardiovascular disease (ASCVD) and downstream cardiovascular (CV) events. However, multiple studies have demonstrated that high-risk patient populations harbour residual risk despite effective LDL-C lowering. While data support the causal relationship between triglycerides and ASCVD risk, triglyceride-lowering therapies such as omega-3 fatty acids have shown mixed results in CV outcomes trials. Notably, icosapent ethyl, a purified formulation of eicosapentaenoic acid (EPA), has garnered compelling evidence in lowering residual CV risk in patients with hypertriglyceridaemia and treated with statins. In this review, we summarize studies that have investigated omega-3-fatty acids for CV event lowering and discuss the clinical implementation of these agents based on trial data and guidelines.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwae003","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:50:30Z","timestamp":1704293430000},"page":"1005-1014","source":"Crossref","is-referenced-by-count":37,"title":["Omega-3 fatty acids for cardiovascular event lowering"],"prefix":"10.1093","volume":"31","author":[{"given":"Gurleen","family":"Kaur","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Preston","family":"Mason","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"},{"name":"Elucida Research LLC , Beverly, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, Public Hospitals of Paris (AP-HP), Bichat Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"2024060223510725900_zwae003-B1","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American heart association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"2024060223510725900_zwae003-B3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia Complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes"},{"key":"2024060223510725900_zwae003-B4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2024060223510725900_zwae003-B6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2024060223510725900_zwae003-B9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2024060223510725900_zwae003-B10","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish oil\u2014how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2024060223510725900_zwae003-B14","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/eurheartj\/ehz778","article-title":"Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics","volume":"41","author":"Boden","year":"2020","journal-title":"Eur Heart J"},{"key":"2024060223510725900_zwae003-B15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacc.2020.11.060","article-title":"Cardiovascular impact of nutritional supplementation with Omega-3 fatty acids: jACC focus seminar","volume":"77","author":"Weinberg","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B16","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jacc.2020.09.005","article-title":"A revolution in Omega-3 fatty acid research","volume":"76","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MOL.0000000000000665","article-title":"Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence","volume":"31","author":"Sherratt","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2024060223510725900_zwae003-B18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-Rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"2024060223510725900_zwae003-B19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.hlc.2015.05.002","article-title":"Analysis of lipoprotein subfractions in Chinese han patients with stable coronary artery disease","volume":"24","author":"Xu","year":"2015","journal-title":"Heart Lung Circ"},{"key":"2024060223510725900_zwae003-B21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCRESAHA.115.306398","article-title":"Surprises from genetic analyses of lipid risk factors for atherosclerosis","volume":"118","author":"Musunuru","year":"2016","journal-title":"Circ Res"},{"key":"2024060223510725900_zwae003-B22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"2024060223510725900_zwae003-B23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCOUTCOMES.115.002104","article-title":"Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry","volume":"9","author":"Klempfner","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2024060223510725900_zwae003-B24","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/jc.2018-00470","article-title":"Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol","volume":"103","author":"Nichols","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024060223510725900_zwae003-B25","doi-asserted-by":"crossref","first-page":"e008740","DOI":"10.1161\/JAHA.118.008740","article-title":"High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk","volume":"7","author":"Toth","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024060223510725900_zwae003-B26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglycerides and impact on global health outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/HCO.0000000000000678","article-title":"Cardiovascular risk reduction with icosapent ethyl","volume":"34","author":"Patel","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"2024060223510725900_zwae003-B28","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan A","year":"2022","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024060223510725900_zwae003-B30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"2024060223510725900_zwae003-B31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr lowering very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2024060223510725900_zwae003-B32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"2024060223510725900_zwae003-B33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the Omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024060223510725900_zwae003-B34","doi-asserted-by":"crossref","first-page":"102337","DOI":"10.1016\/j.plefa.2021.102337","article-title":"Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability","volume":"173","author":"Sherratt","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2024060223510725900_zwae003-B35","doi-asserted-by":"crossref","first-page":"100106","DOI":"10.1016\/j.jlr.2021.100106","article-title":"EPA and DHA containing phospholipids have contrasting effects on membrane structure","volume":"62","author":"Sherratt","year":"2021","journal-title":"J Lipid Res"},{"key":"2024060223510725900_zwae003-B36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.01.002","article-title":"Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction","volume":"212","author":"Sherratt","year":"2018","journal-title":"Chem Phys Lipids"},{"key":"2024060223510725900_zwae003-B37","doi-asserted-by":"crossref","first-page":"183254","DOI":"10.1016\/j.bbamem.2020.183254","article-title":"Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro","volume":"1862","author":"Sherratt","year":"2020","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"2024060223510725900_zwae003-B38","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.bpj.2021.04.009","article-title":"EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol","volume":"120","author":"Jacobs","year":"2021","journal-title":"Biophys J"},{"key":"2024060223510725900_zwae003-B39","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"2024060223510725900_zwae003-B40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"key":"2024060223510725900_zwae003-B41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2018.01.062","article-title":"Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid","volume":"496","author":"Sherratt","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2024060223510725900_zwae003-B42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell'Infarto miocardico","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"2024060223510725900_zwae003-B43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B44","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes Mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B46","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on Major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"Jama"},{"key":"2024060223510725900_zwae003-B47","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77\u202f917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2024060223510725900_zwae003-B49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mayocp.2016.10.018","article-title":"A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain Omega-3 fatty acids and coronary heart disease risk","volume":"92","author":"Alexander","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2024060223510725900_zwae003-B50","doi-asserted-by":"crossref","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine Omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2024060223510725900_zwae003-B51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","article-title":"Effect of Omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2024060223510725900_zwae003-B52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcad.2021.08.003","article-title":"The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization","volume":"69","author":"Bhatt","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"key":"2024060223510725900_zwae003-B53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"2024060223510725900_zwae003-B54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"2024060223510725900_zwae003-B55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"2024060223510725900_zwae003-B56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024060223510725900_zwae003-B57","doi-asserted-by":"crossref","first-page":"e026756","DOI":"10.1161\/JAHA.121.026756","article-title":"Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT","volume":"12","author":"Olshansky","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2024060223510725900_zwae003-B58","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B59","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ehjcvp\/pvaa118","article-title":"REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","volume":"7","author":"Olshansky","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024060223510725900_zwae003-B60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B61","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: rEDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B62","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: rEDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B63","doi-asserted-by":"crossref","first-page":"e022937","DOI":"10.1161\/JAHA.121.022937","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024060223510725900_zwae003-B64","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B65","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2022.03.001","article-title":"Optimizing dyslipidemic cardiovascular residual risk reduction with icosapent ethyl in post-MI patients","volume":"79","author":"Boden","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B66","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B67","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B69","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"2024060223510725900_zwae003-B70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvz329","article-title":"Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography","volume":"116","author":"Lakshmanan","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2024060223510725900_zwae003-B71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2021.11.005","article-title":"Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT","volume":"79","author":"Singh","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B72","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.2021.0824","article-title":"Omega-3 fatty acids effect on Major cardiovascular events in patients at high cardiovascular risk","volume":"325","author":"Olshansky","year":"2021","journal-title":"JAMA"},{"key":"2024060223510725900_zwae003-B73","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio","year":"2014","journal-title":"Atherosclerosis"},{"key":"2024060223510725900_zwae003-B74","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-020-01343-7","article-title":"The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction","volume":"20","author":"Wang","year":"2020","journal-title":"Curr Diab Rep"},{"key":"2024060223510725900_zwae003-B75","doi-asserted-by":"crossref","first-page":"114629","DOI":"10.1016\/j.biopha.2023.114629","article-title":"Eicosapentaenoic acid (EPA) reduces pulmonary endothelial dysfunction and inflammation due to changes in protein expression during exposure to particulate matter air pollution","volume":"162","author":"Sherratt","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2024060223510725900_zwae003-B76","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024060223510725900_zwae003-B77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5551\/jat.25593","article-title":"Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study","volume":"22","author":"Yamano","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"2024060223510725900_zwae003-B78","doi-asserted-by":"crossref","first-page":"e029109","DOI":"10.1161\/JAHA.122.029109","article-title":"Comparative effects of mineral oil, corn oil, eicosapentaenoic acid, and docosahexaenoic acid in an in vitro atherosclerosis model","volume":"12","author":"Sherratt","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2024060223510725900_zwae003-B79","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","article-title":"Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1\u03b2, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2022.11.008","article-title":"Study protocol and baseline characteristics of randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid: rESPECT-EPA, the combination of a randomized control trial and an observational biomarker study","volume":"257","author":"Nishizaki","year":"2022","journal-title":"Am Heart J"},{"key":"2024060223510725900_zwae003-B81","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J Cardiol"},{"key":"2024060223510725900_zwae003-B82","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results","volume":"117","author":"Budoff","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2024060223510725900_zwae003-B83","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"2024060223510725900_zwae003-B84","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41430-019-0551-5","article-title":"Early-onset coronary atherosclerosis in patients with low levels of omega-3 fatty acids","volume":"74","author":"Bittner","year":"2020","journal-title":"Eur J Clin Nutr"},{"key":"2024060223510725900_zwae003-B85","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/ehjci\/jead063","article-title":"Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: eVAPORATE-FFRCT","volume":"24","author":"Rabbat","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024060223510725900_zwae003-B86","article-title":"Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use","author":"Gaba","year":"2023","journal-title":"Eur Heart J"},{"key":"2024060223510725900_zwae003-B87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/fca-2020-0106","article-title":"Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction","volume":"17","author":"Boden","year":"2021","journal-title":"Future Cardiol"},{"key":"2024060223510725900_zwae003-B88","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"2024060223510725900_zwae003-B89","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B90","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/HCO.0000000000000800","article-title":"Generalizability of reduction of cardiovascular events with icosapent ethyl-intervention trial in patients with a history of coronary artery bypass graft surgery","volume":"36","author":"Kosmopoulos","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2024060223510725900_zwae003-B91","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/clc.23437","article-title":"Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?","volume":"43","author":"Ferri\u00e8res","year":"2020","journal-title":"Clin Cardiol"},{"key":"2024060223510725900_zwae003-B92","doi-asserted-by":"crossref","first-page":"e2148172","DOI":"10.1001\/jamanetworkopen.2021.48172","article-title":"Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment","volume":"5","author":"Weintraub","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024060223510725900_zwae003-B93","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"2024060223510725900_zwae003-B94","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2024060223510725900_zwae003-B95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024060223510725900_zwae003-B96","first-page":"429","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC)","volume":"75","author":"Visseren","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2024060223510725900_zwae003-B97","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National lipid association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2024060223510725900_zwae003-B98","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jacc.2020.08.073","article-title":"Circulating Omega-3 fatty acids and incident adverse events in patients with acute myocardial infarction","volume":"76","author":"L\u00e1zaro","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024060223510725900_zwae003-B99","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbrc.2016.12.127","article-title":"Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits","volume":"483","author":"Mason","year":"2017","journal-title":"Biochem Biophys Res Commun"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae003\/56410322\/zwae003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/8\/1005\/58009495\/zwae003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/8\/1005\/58009495\/zwae003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T23:52:07Z","timestamp":1717372327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/8\/1005\/7505348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":99,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae003","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,1,3]]}}}